Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Muscular Diseases | 3 | 2020 | 61 | 0.810 |
Why?
|
Dopamine Antagonists | 1 | 2018 | 21 | 0.650 |
Why?
|
Thiazoles | 1 | 2018 | 53 | 0.640 |
Why?
|
Piperazines | 1 | 2018 | 118 | 0.600 |
Why?
|
Muscular Dystrophies | 2 | 2020 | 15 | 0.310 |
Why?
|
Phenotype | 3 | 2020 | 733 | 0.280 |
Why?
|
Mutation | 4 | 2020 | 1294 | 0.240 |
Why?
|
Fasciculation | 1 | 2020 | 2 | 0.190 |
Why?
|
Isaacs Syndrome | 1 | 2020 | 2 | 0.190 |
Why?
|
Hereditary Sensory and Motor Neuropathy | 1 | 2020 | 3 | 0.180 |
Why?
|
Spinal Muscular Atrophies of Childhood | 1 | 2020 | 9 | 0.180 |
Why?
|
Myopathies, Structural, Congenital | 1 | 2020 | 10 | 0.180 |
Why?
|
Codon, Nonsense | 1 | 2020 | 26 | 0.180 |
Why?
|
Oligonucleotides | 1 | 2020 | 81 | 0.180 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2020 | 86 | 0.170 |
Why?
|
Recombinant Fusion Proteins | 1 | 2020 | 186 | 0.170 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2020 | 198 | 0.170 |
Why?
|
Tourette Syndrome | 1 | 2018 | 10 | 0.160 |
Why?
|
Creatine Kinase | 1 | 2018 | 30 | 0.160 |
Why?
|
Cardiovascular Abnormalities | 1 | 2019 | 26 | 0.160 |
Why?
|
Growth Disorders | 1 | 2019 | 64 | 0.160 |
Why?
|
Nerve Tissue Proteins | 1 | 2020 | 193 | 0.160 |
Why?
|
Obsessive-Compulsive Disorder | 1 | 2018 | 43 | 0.160 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2019 | 157 | 0.160 |
Why?
|
Thymidine Kinase | 1 | 2018 | 19 | 0.160 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2019 | 140 | 0.160 |
Why?
|
Early Ambulation | 1 | 1997 | 6 | 0.150 |
Why?
|
Thrombophlebitis | 1 | 1997 | 24 | 0.150 |
Why?
|
Immobilization | 1 | 1997 | 14 | 0.150 |
Why?
|
Mitochondrial Diseases | 1 | 2018 | 42 | 0.150 |
Why?
|
Physical Therapy Modalities | 1 | 1997 | 36 | 0.150 |
Why?
|
DNA, Mitochondrial | 1 | 2018 | 113 | 0.140 |
Why?
|
Pulmonary Embolism | 1 | 1997 | 97 | 0.140 |
Why?
|
Dystroglycans | 1 | 2015 | 2 | 0.130 |
Why?
|
Nucleotidyltransferases | 1 | 2015 | 14 | 0.130 |
Why?
|
Muscle, Skeletal | 2 | 2018 | 765 | 0.130 |
Why?
|
Mitochondria | 1 | 2018 | 404 | 0.120 |
Why?
|
Male | 10 | 2020 | 25399 | 0.120 |
Why?
|
Transcription Factors | 1 | 2017 | 564 | 0.120 |
Why?
|
Signal Transduction | 1 | 2019 | 1622 | 0.100 |
Why?
|
Child | 7 | 2020 | 6851 | 0.100 |
Why?
|
Quadriplegia | 1 | 1991 | 9 | 0.100 |
Why?
|
Humans | 13 | 2020 | 50208 | 0.100 |
Why?
|
Anxiety Disorders | 1 | 1991 | 126 | 0.090 |
Why?
|
Adolescent | 6 | 2020 | 6390 | 0.090 |
Why?
|
Infant | 4 | 2020 | 3563 | 0.090 |
Why?
|
Child, Preschool | 4 | 2020 | 3883 | 0.080 |
Why?
|
Adult | 4 | 2018 | 13324 | 0.080 |
Why?
|
Respiration, Artificial | 1 | 1991 | 274 | 0.080 |
Why?
|
Young Adult | 4 | 2019 | 3981 | 0.080 |
Why?
|
Genetic Association Studies | 2 | 2019 | 116 | 0.070 |
Why?
|
Female | 8 | 2020 | 26635 | 0.070 |
Why?
|
Spinal Cord Injuries | 1 | 2005 | 55 | 0.060 |
Why?
|
Program Development | 1 | 2005 | 167 | 0.060 |
Why?
|
Brain Injuries | 1 | 2005 | 157 | 0.050 |
Why?
|
Social Support | 1 | 2005 | 264 | 0.050 |
Why?
|
Parents | 1 | 2005 | 315 | 0.050 |
Why?
|
Patient Education as Topic | 1 | 2005 | 313 | 0.050 |
Why?
|
Dystrophin | 1 | 2020 | 5 | 0.050 |
Why?
|
Muscle Cramp | 1 | 2020 | 5 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 2 | 2019 | 1541 | 0.040 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2019 | 20 | 0.040 |
Why?
|
Facies | 1 | 2019 | 35 | 0.040 |
Why?
|
Drug Therapy, Combination | 1 | 2020 | 381 | 0.040 |
Why?
|
Prader-Willi Syndrome | 1 | 2017 | 7 | 0.040 |
Why?
|
Muscle Hypotonia | 1 | 2017 | 21 | 0.040 |
Why?
|
Exome | 1 | 2017 | 46 | 0.040 |
Why?
|
Ataxia | 1 | 2017 | 20 | 0.040 |
Why?
|
Conserved Sequence | 1 | 2017 | 56 | 0.040 |
Why?
|
Phosphorylation | 1 | 2019 | 534 | 0.040 |
Why?
|
Retrospective Studies | 2 | 2020 | 6134 | 0.040 |
Why?
|
Incidence | 2 | 1997 | 1006 | 0.040 |
Why?
|
Energy Metabolism | 1 | 2019 | 279 | 0.040 |
Why?
|
Developmental Disabilities | 1 | 2017 | 119 | 0.030 |
Why?
|
Amino Acid Sequence | 1 | 2017 | 586 | 0.030 |
Why?
|
Intellectual Disability | 1 | 2017 | 124 | 0.030 |
Why?
|
Autistic Disorder | 1 | 2017 | 120 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2019 | 509 | 0.030 |
Why?
|
Heterozygote | 1 | 2015 | 81 | 0.030 |
Why?
|
Alleles | 1 | 2015 | 251 | 0.030 |
Why?
|
Spinal Dysraphism | 1 | 1994 | 37 | 0.030 |
Why?
|
Aged | 2 | 2018 | 9405 | 0.030 |
Why?
|
Disabled Persons | 1 | 1994 | 75 | 0.030 |
Why?
|
Biopsy | 1 | 2015 | 590 | 0.030 |
Why?
|
Prognosis | 1 | 2018 | 1954 | 0.030 |
Why?
|
Middle Aged | 2 | 2018 | 12206 | 0.030 |
Why?
|
Relaxation Therapy | 1 | 1991 | 6 | 0.020 |
Why?
|
Nonverbal Communication | 1 | 1991 | 14 | 0.020 |
Why?
|
Time Factors | 1 | 1997 | 2922 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2018 | 2766 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 1997 | 3154 | 0.020 |
Why?
|
Treatment Outcome | 1 | 2020 | 5155 | 0.020 |
Why?
|
Heart Rate | 1 | 1991 | 298 | 0.020 |
Why?
|
Risk Factors | 1 | 1997 | 3629 | 0.020 |
Why?
|
Brain | 1 | 2015 | 1328 | 0.020 |
Why?
|
Family Health | 1 | 2005 | 80 | 0.020 |
Why?
|
Program Evaluation | 1 | 2005 | 354 | 0.010 |
Why?
|
Education, Special | 1 | 1994 | 10 | 0.010 |
Why?
|
Rehabilitation, Vocational | 1 | 1994 | 23 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 1994 | 1554 | 0.010 |
Why?
|
Arkansas | 1 | 1994 | 1985 | 0.000 |
Why?
|